Scarica l'app Stockscreener
0.9948
3.63%
0.0348
Dopo l'orario di chiusura:
.98
-0.0148
-1.49%
Cardiol Therapeutics Inc Borsa (CRDL) Ultime notizie
Cardiol Therapeutics (TSE:CRDL) Shares Down 7.1% – Time to Sell? - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Upgraded at Brookline Capital Management - Defense World
(CRDL) Market Dynamics and Trading Signals (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics files underwriting agreement and warrant indenture By Investing.com - Investing.com Nigeria
Cardiol Therapeutics files underwriting agreement and warrant indenture - Investing.com
Cardiol Therapeutics Secures $14.85 Million Bought-Deal Unit Financing - TipRanks
Targets Report: Can Cardiol Therapeutics Inc weather a recessionPortfolio Profit Report & Daily Growth Stock Tips - baoquankhu1.vn
Fund Flows: Will Ambarella Inc stock benefit from M A2025 Trading Volume Trends & Safe Swing Trade Setups - baoquankhu1.vn
Aug Retail: Is MPWR in a bullish channel2025 Volatility Report & Daily Entry Point Trade Alerts - baoquankhu1.vn
(CRDL) Strategic Equity Report (CRDL:CA) - Stock Traders Daily
Can Cardiol Therapeutics Inc. weather a recessionJuly 2025 Analyst Calls & Verified Technical Trade Signals - mfd.ru
Cardiol Therapeutics Secures U.S. Patent for Heart Drugs - MSN
Cardiol Therapeutics Secures $13.5 Million Bought-Deal Financing to Advance Heart Disease Programs - TipRanks
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million - Investing News Network
When the Price of (CRDL) Talks, People Listen (CRDL:CA) - Stock Traders Daily
Heart disease biotech Cardiol raises $14.85M for trials - stocktitan.net
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million - Yahoo Finance
(CRDL) Equity Trading Insights (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics announces $13.5M bought-deal private placement - MSN
Will Cardiol Therapeutics Inc. (CT9) stock gain from lower interest ratesChart Pattern Recognition & Free Discover Fast Growing Stocks - bollywoodhelpline.com
Why Cardiol Therapeutics Inc. stock is favored by top institutionsCup and Handle Formations & Identify Breakout Stocks - bollywoodhelpline.com
Portfolio Shifts: Will Cardiol Therapeutics Inc outperform tech stocksTake Profit & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Cardiol Therapeutics announces $13.5 million private placement By Investing.com - Investing.com Nigeria
(CRDL) Technical Pivots with Risk Controls (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics announces $13.5 million bought deal financing By Investing.com - Investing.com Nigeria
Cardiol Therapeutics Inc. announced that it expects to receive CAD 13.500001 million in funding - marketscreener.com
Cardiol Therapeutics Secures $13.5 Million Bought Deal Financing to Advance Heart Disease Programs - TipRanks
Cardiol Therapeutics announces $13.5 million private placement - Investing.com
Cardiol Therapeutics announces $13.5 million bought deal financing - Investing.com
Heart drug developer Cardiol lines up $13.5M to fund trials and research - Stock Titan
AI Stocks: Is NeuroSense Therapeutics Ltd Equity Warrant forming a bullish divergenceJuly 2025 Fed Impact & AI Enhanced Trading Signals - baoquankhu1.vn
Cardiol Therapeutics to Raise $13.5 Million in a Bought-Deal Private Placement of Share-Units - marketscreener.com
Cardiol Therapeutics (TSE:CRDL) Stock Price Up 1.5% – Still a Buy? - Defense World
Cardiol Therapeutics (TSE:CRDL) Stock Price Up 1.5%Still a Buy? - MarketBeat
(CRDL) On The My Stocks Page (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Receives $8.00 Consensus Price Target from Analysts - Defense World
Insider Sell: Is Cardiol Therapeutics Inc stock a safe investment in uncertain markets2025 EndofYear Setup & Consistent Return Strategy Ideas - Bộ Nội Vụ
Cardiol Therapeutics reaches 50% enrollment in recurrent pericarditis trial By Investing.com - Investing.com Nigeria
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
Cardiol Therapeutics Reaches 50% Enrollment in Pivotal Phase III MAVERIC Trial for Recurrent Pericarditis - TipRanks
Cardiol Therapeutics reaches 50% enrollment in recurrent pericarditis trial - Investing.com
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis - Investing News Network
Cardiol Therapeutics (NASDAQ: CRDL) reaches 50% MAVERIC Phase III enrollment - Stock Titan
Aug Movers: Can Cardiol Therapeutics Inc maintain its current growth rateJuly 2025 Weekly Recap & High Conviction Trade Alerts - baoquankhu1.vn
Analysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before Long - Yahoo Finance
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
(CRDL) Stock Trading Blueprint (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics Reports Financial Challenges Amid Clinical Progress - MSN
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):